← Back to Search

Corticosteroid

Dexamethasone Administration for Respiratory Syncytial Virus Bronchiolitis (BroncHI Trial)

Phase < 1
Waitlist Available
Research Sponsored by IDeA States Pediatric Clinical Trials Network
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up intervention: 72 hours; follow-up: 30 days
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to see if dexamethasone can be effectively given to infants with bronchiolitis. The medication helps reduce inflammation in their airways, making it easier for them to breathe. The study focuses on infants with certain health histories. Dexamethasone has been studied in various trials for its effectiveness in treating respiratory conditions in infants, including bronchiolitis and bronchopulmonary dysplasia.

Eligible Conditions
  • Respiratory Syncytial Virus Bronchiolitis
  • Bronchiolitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~intervention: 72 hours; follow-up: 30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and intervention: 72 hours; follow-up: 30 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants that receive 2 doses of dexamethasone per protocol.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Dexamethasone AdministrationExperimental Treatment1 Intervention
Dexamethasone will be given orally to all consented participants. Two doses will be administered within 12-48 hours, with at least the 1st dose administered during the bronchiolitis hospitalization. If the participant is discharged before the 2nd dose, it will be administered at home.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dexamethasone Oral
2020
N/A
~14110

Find a Location

Who is running the clinical trial?

IDeA States Pediatric Clinical Trials NetworkLead Sponsor
6 Previous Clinical Trials
1,257 Total Patients Enrolled
National Institutes of Health (NIH)NIH
2,812 Previous Clinical Trials
8,161,471 Total Patients Enrolled
University of NebraskaOTHER
555 Previous Clinical Trials
1,145,384 Total Patients Enrolled

Media Library

Dexamethasone (Corticosteroid) Clinical Trial Eligibility Overview. Trial Name: NCT05994183 — Phase < 1
Respiratory Syncytial Virus Bronchiolitis Research Study Groups: Dexamethasone Administration
Respiratory Syncytial Virus Bronchiolitis Clinical Trial 2023: Dexamethasone Highlights & Side Effects. Trial Name: NCT05994183 — Phase < 1
Dexamethasone (Corticosteroid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05994183 — Phase < 1
~0 spots leftby Mar 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top